中华传染病杂志
中華傳染病雜誌
중화전염병잡지
CHINESE JOURNAL OF INFECTIOUS DISEASES
2010年
8期
484-487
,共4页
周慧%王福祥%周海舟%马英骥
週慧%王福祥%週海舟%馬英驥
주혜%왕복상%주해주%마영기
HIV-1%反转录酶抑制剂%HIV蛋白酶抑制剂%突变%基因型%抗药性,病毒
HIV-1%反轉錄酶抑製劑%HIV蛋白酶抑製劑%突變%基因型%抗藥性,病毒
HIV-1%반전록매억제제%HIV단백매억제제%돌변%기인형%항약성,병독
HIV-1%Reverse transcriptase inhibitors%HIV protease inhibitors%Mutation%Genotype%Drug resistance,viral
目的 对黑龙江省流行的HIV-1毒株的蛋白酶基因及反转录酶基因进行基因型耐药分析,为开展大规模临床抗病毒治疗提供本底数据.方法 采用套式-PCR法扩增黑龙江省内49例HIV-1感染者及AIDS患者外周血单个核细胞中前病毒cDNA的部分蛋白酶和反转录酶基因,分析基因序列,与国际耐药数据库比对,分析耐药变异.结果 49例患者HIV毒株亚型分析为B'亚型.在扩增出蛋白酶基因的47份标本中,未发现对蛋白酶抑制剂的原发突变,但发现大量对蛋白酶抑制剂的次要突变,V771占91.5%、L63P占76.6%、I93L占74.5%、E35D占61.7%、R57K占19.1%、R41K占10.6%、A71V占8.5%、M36I占8.5%、L10I占6.4%、D60E占6.4%、L89M占4.2%和G16E占2.1%.在扩增出反转录酶基因的44份标本中,1份有反转录酶抑制剂的原发突变M184I,占2.3%,均有反转录酶抑制剂的次要突变,I135L/T/R/V占81.8%、V106I占22.7%、V179D/E占11.4%、R211K占9.1%、L214F占4.5%、V189I占4.5%和V108I占2.3%.结论 目前在黑龙江省未接受抗反转录病毒治疗的患者中未发现对蛋白酶抑制剂耐药的原发突变,耐药突变处于低水平,但应及时进行耐药突变检测,防止多重耐药和交叉耐药的出现和流行.
目的 對黑龍江省流行的HIV-1毒株的蛋白酶基因及反轉錄酶基因進行基因型耐藥分析,為開展大規模臨床抗病毒治療提供本底數據.方法 採用套式-PCR法擴增黑龍江省內49例HIV-1感染者及AIDS患者外週血單箇覈細胞中前病毒cDNA的部分蛋白酶和反轉錄酶基因,分析基因序列,與國際耐藥數據庫比對,分析耐藥變異.結果 49例患者HIV毒株亞型分析為B'亞型.在擴增齣蛋白酶基因的47份標本中,未髮現對蛋白酶抑製劑的原髮突變,但髮現大量對蛋白酶抑製劑的次要突變,V771佔91.5%、L63P佔76.6%、I93L佔74.5%、E35D佔61.7%、R57K佔19.1%、R41K佔10.6%、A71V佔8.5%、M36I佔8.5%、L10I佔6.4%、D60E佔6.4%、L89M佔4.2%和G16E佔2.1%.在擴增齣反轉錄酶基因的44份標本中,1份有反轉錄酶抑製劑的原髮突變M184I,佔2.3%,均有反轉錄酶抑製劑的次要突變,I135L/T/R/V佔81.8%、V106I佔22.7%、V179D/E佔11.4%、R211K佔9.1%、L214F佔4.5%、V189I佔4.5%和V108I佔2.3%.結論 目前在黑龍江省未接受抗反轉錄病毒治療的患者中未髮現對蛋白酶抑製劑耐藥的原髮突變,耐藥突變處于低水平,但應及時進行耐藥突變檢測,防止多重耐藥和交扠耐藥的齣現和流行.
목적 대흑룡강성류행적HIV-1독주적단백매기인급반전록매기인진행기인형내약분석,위개전대규모림상항병독치료제공본저수거.방법 채용투식-PCR법확증흑룡강성내49례HIV-1감염자급AIDS환자외주혈단개핵세포중전병독cDNA적부분단백매화반전록매기인,분석기인서렬,여국제내약수거고비대,분석내약변이.결과 49례환자HIV독주아형분석위B'아형.재확증출단백매기인적47빈표본중,미발현대단백매억제제적원발돌변,단발현대량대단백매억제제적차요돌변,V771점91.5%、L63P점76.6%、I93L점74.5%、E35D점61.7%、R57K점19.1%、R41K점10.6%、A71V점8.5%、M36I점8.5%、L10I점6.4%、D60E점6.4%、L89M점4.2%화G16E점2.1%.재확증출반전록매기인적44빈표본중,1빈유반전록매억제제적원발돌변M184I,점2.3%,균유반전록매억제제적차요돌변,I135L/T/R/V점81.8%、V106I점22.7%、V179D/E점11.4%、R211K점9.1%、L214F점4.5%、V189I점4.5%화V108I점2.3%.결론 목전재흑룡강성미접수항반전록병독치료적환자중미발현대단백매억제제내약적원발돌변,내약돌변처우저수평,단응급시진행내약돌변검측,방지다중내약화교차내약적출현화류행.
Objective To study the presence of drug resistant mutations of protease and reverse transcriptase among human immunodeficiency virus (HIV)-1 strains isolated from treatment naive HIV/ acquired immune deficiency syndrome (AIDS) patients in Heilongjiang Province of China and to provide the baseline data for starting antiretroviral therapy in this area. Methods The protease and reverse transcriptase gene sequences were amplified by nested-polymerase chain reaction (PCR) and then sequenced. The results were compared to the subtype B consensus amino acid sequence and analyzed with Stanford HIV-db drug resistance sequence interpretation. Results The results showed that HIV strains from 49 patients were classified as subtype B'. No primary mutations associated with protease inhibitor were detected. Some secondary mutations associated with protease inhibitor were detected, which included V77I(91.5%), L63P(76.6%), I93L(74.5%), E35D(61.7%), R57K (19.1%), R41K(10.6%), A71V(8.5%), M36I(8.5%), L10I(6.4%), D60E(6.4%), L89M (4.2%) and G16E(2. 1%). Only one case had a primary mutation M184I that was associated with resistance to reverse transcriptase inhibitors. However, many secondary mutations associated with resistance to reverse transcriptase inhibitors were found, including I135L/T/R/V(81.8%), V106I(22.7%), V179D/E(11.4%), R211K(9.1%), L214F(4.5%), V189I(4.5%) and V108I(2. 3%).Conclusions The prevalence of genotypic anti-HIV drug resistance is very low in treatment naive HIV/AIDS patients in Heilongjiang Province. However, closely monitoring on drug resistance mutation is very important for preventing the development and prevalence of multi-drug resistant or cross drug resistant HIV.
